Next Article in Journal
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Next Article in Special Issue
YAP/TAZ Activation as a Target for Treating Metastatic Cancer
Previous Article in Journal
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Previous Article in Special Issue
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Cancers 2018, 10(4), 94;

The Hippo Pathway: Immunity and Cancer

Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 9 March 2018 / Revised: 23 March 2018 / Accepted: 26 March 2018 / Published: 28 March 2018
Full-Text   |   PDF [13761 KB, uploaded 3 May 2018]   |  


Since its discovery, the Hippo pathway has emerged as a central signaling network in mammalian cells. Canonical signaling through the Hippo pathway core components (MST1/2, LATS1/2, YAP and TAZ) is important for development and tissue homeostasis while aberrant signaling through the Hippo pathway has been implicated in multiple pathologies, including cancer. Recent studies have uncovered new roles for the Hippo pathway in immunology. In this review, we summarize the mechanisms by which Hippo signaling in pathogen-infected or neoplastic cells affects the activities of immune cells that respond to these threats. We further discuss how Hippo signaling functions as part of an immune response. Finally, we review how immune cell-intrinsic Hippo signaling modulates the development/function of leukocytes and propose directions for future work. View Full-Text
Keywords: Hippo pathway; cancer; immunology; immunotherapy; inflammation; MST1/2; LATS1/2; YAP; TAZ; PD-L1 Hippo pathway; cancer; immunology; immunotherapy; inflammation; MST1/2; LATS1/2; YAP; TAZ; PD-L1

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Taha, Z.; Janse van Rensburg, H.J.; Yang, X. The Hippo Pathway: Immunity and Cancer. Cancers 2018, 10, 94.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top